Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jul;49(7):2311-2324.
doi: 10.1007/s00261-024-04418-1. Epub 2024 Jun 15.

Multimodal data integration using machine learning to predict the risk of clear cell renal cancer metastasis: a retrospective multicentre study

YouChang Yang #  1 , JiaJia Wang #  2 , QingGuo Ren  1 , Rong Yu  3 , ZiYi Yuan  2 , QingJun Jiang  1 , Shuai Guan  1 , XiaoQiang Tang  4 , TongTong Duan  5 , XiangShui Meng  6
Affiliations
Multicenter Study

Multimodal data integration using machine learning to predict the risk of clear cell renal cancer metastasis: a retrospective multicentre study

YouChang Yang et al. Abdom Radiol (NY). 2024 Jul.

Abstract

Purpose: To develop and validate a predictive combined model for metastasis in patients with clear cell renal cell carcinoma (ccRCC) by integrating multimodal data.

Materials and methods: In this retrospective study, the clinical and imaging data (CT and ultrasound) of patients with ccRCC confirmed by pathology from three tertiary hospitals in different regions were collected from January 2013 to January 2023. We developed three models, including a clinical model, a radiomics model, and a combined model. The performance of the model was determined based on its discriminative power and clinical utility. The evaluation indicators included area under the receiver operating characteristic curve (AUC) value, accuracy, sensitivity, specificity, negative predictive value, positive predictive value and decision curve analysis (DCA) curve.

Results: A total of 251 patients were evaluated. Patients (n = 166) from Shandong University Qilu Hospital (Jinan) were divided into the training cohort, of which 50 patients developed metastases; patients (n = 37) from Shandong University Qilu Hospital (Qingdao) were used as internal testing, of which 15 patients developed metastases; patients (n = 48) from Changzhou Second People's Hospital were used as external testing, of which 13 patients developed metastases. In the training set, the combined model showed the highest performance (AUC, 0.924) in predicting lymph node metastasis (LNM), while the clinical and radiomics models both had AUCs of 0.845 and 0.870, respectively. In the internal testing, the combined model had the highest performance (AUC, 0.877) for predicting LNM, while the AUCs of the clinical and radiomics models were 0.726 and 0.836, respectively. In the external testing, the combined model had the highest performance (AUC, 0.849) for predicting LNM, while the AUCs of the clinical and radiomics models were 0.708 and 0.804, respectively. The DCA curve showed that the combined model had a significant prediction probability in predicting the risk of LNM in ccRCC patients compared with the clinical model or the radiomics model.

Conclusion: The combined model was superior to the clinical and radiomics models in predicting LNM in ccRCC patients.

Keywords: Clear cell renal cell carcinoma; Deep learning; Metastasis; Multimodal data.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/ https://doi.org/10.3322/caac.21492 - DOI - PubMed
    1. Gonzalez Leon T, Morera Perez M (2016) Renal Cancer in the Elderly. Curr Urol Rep 17:6. https://doi.org/ https://doi.org/10.1007/s11934-015-0562-2 - DOI - PubMed
    1. Motzer RJ, Agarwal N, Beard C, Bolger GB, Boston B, Carducci MA, Choueiri TK, Figlin RA, Fishman M, Hancock SL, Hudes GR, Jonasch E, Kessinger A, Kuzel TM, Lange PH, Levine EG, Margolin KA, Michaelson MD, Olencki T, Pili R, Redman BG, Robertson CN, Schwartz LH, Sheinfeld J, Wang J (2009) NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw 7:618–630. https://doi.org/ https://doi.org/10.6004/jnccn.2009.0043 - DOI - PubMed
    1. Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S, Giles RH, Hofmann F, Hora M, Kuczyk MA, Kuusk T, Lam TB, Marconi L, Merseburger AS, Powles T, Staehler M, Tahbaz R, Volpe A, Bex A (2019) European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. Eur Urol 75:799–810. https://doi.org/ https://doi.org/10.1016/j.eururo.2019.02.011 - DOI - PubMed
    1. Xing T, He H (2016) Epigenomics of clear cell renal cell carcinoma: mechanisms and potential use in molecular pathology. Chin J Cancer Res 28:80–91. https://doi.org/ https://doi.org/10.3978/j.issn.1000-9604.2016.02.09 - DOI - PubMed - PMC

Publication types